What We're Reading: Page 378
Industry reads hand-picked by our editors
Mar 04, 2015
-
Fierce Pharma
AZ board to CEO Soriot: Want that big bonus? Show us the money
-
-
-
Celgene's Abraxane approved in EU for first-line treatement of NSCLC
-
US lawmakers push Amphastar for answers on naloxone prices
-
-
-
Survey: New Genentech distribution policy delaying cancer patients' care
-
-
Gilead seals generic Sovaldi deal with Natco, NICE rec for Harvoni in UK
Mar 03, 2015
-
-
-
-
BMS' Opdivo wins lung cancer indication more than 3 months before PDUFA date
-
Ousted Sanofi chief Chris Viebacher lands at PureTech
-
How 23andMe used rigorous clinical trials to win a landmark FDA authorization
-
A biotech is bringing a new IUD to market—but the company's a nonprofit
-
-
-
Indian advisory board proposes waiving phase III for certain drugs
Mar 02, 2015
-
Positive phase II Provenge data a good early sign for ambitious Valeant
-
-
-
-
EU approves first new chemical entity for Parkinson's in a decade
-
-
A booming Bayer projects 10% pharma-driven growth in 2015
-
Gilead raking in billions off of foreign tax laws
-
GSK's CEO faces another pay cut—and it's a big one
-
Feb 27, 2015
-
-
-
UPDATE: Sanofi's likely blockbuster insulin Toujeo wins FDA approval
-
Federal judge strikes down Maine's controversial prescription drug import law
-
-
Game time: Remicade biosims from Celltrion, Hospira launch in big EU markets
-
-
CA lawmaker to pharma: Show us, with numbers, why drugs cost so much
-
Pharmacyclics surges on news of potential sale to J&J, Novartis
-
FDA approves Actavis' QIDP-designated antibiotic combo
Feb 26, 2015
-
Pfizer planning more layoffs in R&D
-
Merck, MPP team up to provide low-cost HIV pediatric meds in poor countries
-
-
-
French government slams Sanofi over new CEO's pay
-
-
Public Citizen requests FDA ban on certain antifungal meds
-
-
Shire keeps acquisition train rolling with $70M Meritage Pharma deal
-
Platinum parachute? Allergan CEO Pyott could get $100M exit fee
Feb 25, 2015
-
BMS strengthens oncology pipeline with two big deals worth $1.6B
-
-
Lilly's long-acting insulin not ready for prime time
-
Toronto Star retracts piece suggesting injuries linked to Merck's Gardasil
-
-
-
Duchenne, orphan drug maker PTC Therapeutics fielding takeover bids
-
-
Novartis' Farydak wins FDA approval for multiple myeloma
-
Is there still a place for the mighty pharmaceutical sales force?
Feb 24, 2015
-
FDA to review Pfizer's rare lung disease drug for women
-
UPDATE: Valeant to buy Salix for $10.1B, cleared for $495M Dendreon buyout
-
Compounding pharmacies chafe at FDA's disciplinary actions
-
-
Corgenix's 15-minute Ebola test approved by WHO
-
-
-
Holoclar makes history: Europe approves West's first stem-cell therapy
-
Cellectis files $115M IPO to fund unique CAR-T program
-
Previous
